Imunon, Inc. Proceeds from Notes Payable
Imunon, Inc. (IMNN) reported Proceeds from Notes Payable of $7.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-11
- Imunon, Inc. proceeds from notes payable for the quarter ending 2018-12-31 was $0.00.
- Imunon, Inc. proceeds from notes payable for the quarter ending 2018-09-30 was $0.00.
- Imunon, Inc. proceeds from notes payable for the quarter ending 2014-12-31 was $0.00.
- Imunon, Inc. proceeds from notes payable for the quarter ending 2014-09-30 was $0.00.
- Imunon, Inc. proceeds from notes payable for fiscal 2021 was $5.76M.
- Imunon, Inc. proceeds from notes payable for fiscal 2018 was $9.72M.
- Imunon, Inc. proceeds from notes payable for fiscal 2014 was $5.00M, a 4.96% increase from fiscal 2013.
- Imunon, Inc. proceeds from notes payable for fiscal 2013 was $4.76M, a 1.28% decline from fiscal 2012.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.03M 10-Q · filed 2026-08-11 | |||
| 2021-12-31 | $5.76M 10-K · filed 2023-03-30 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $0.00 derived: sum of 2 quarters · filed 2020-03-25 | $9.72M 10-K · filed 2020-03-25 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $9.72M 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $9.72M 10-Q · filed 2019-08-14 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 derived: sum of 2 quarters · filed 2016-03-30 | $5.00M 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $5.00M 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | $5.00M 10-Q · filed 2015-08-10 | |||
| 2013-12-31 | $4.76M 10-K · filed 2016-03-30 | |||
| 2012-12-31 | $11.10K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$27.64K derived: sum of 2 quarters · filed 2015-03-12 | $4.83M 10-K · filed 2015-03-12 | |
| 2012-09-30 | -$38.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $4.81M 10-Q · filed 2013-11-12 | ||
| 2012-06-30 | $4.85M 10-Q · filed 2013-08-08 | |||
| 2011-12-31 | $144.45K 10-K · filed 2014-03-13 | |||
| 2010-12-31 | $0.00 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |